Loading…
Top-line therapeutic data expected in early fall.
Valion Bio, Inc. announced that its drug candidate, Entolimod, is scheduled to undergo a government-funded safety study aimed at treating radiation-induced gastrointestinal injury. The study is expected to yield top-line therapeutic data by early fall.
The company did not provide specific financial details or share considerations related to this announcement. As of the latest data, Valion Bio has a free float of 3,065,990 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.